Log in

NASDAQ:NURONeurometrix Stock Price, Forecast & News

+0.10 (+4.65 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $2.25
50-Day Range
MA: $2.02
52-Week Range
Now: $2.25
Volume722,763 shs
Average Volume321,818 shs
Market Capitalization$8.51 million
P/E RatioN/A
Dividend YieldN/A
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.
Read More
Neurometrix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:NURO



Sales & Book Value

Annual Sales$9.27 million
Book Value$1.45 per share


Net Income$-3,770,000.00


Market Cap$8.51 million
Next Earnings Date10/15/2020 (Estimated)
OptionableNot Optionable
+0.10 (+4.65 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Neurometrix (NASDAQ:NURO) Frequently Asked Questions

How has Neurometrix's stock been impacted by COVID-19 (Coronavirus)?

Neurometrix's stock was trading at $1.41 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NURO stock has increased by 59.6% and is now trading at $2.25.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Neurometrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Neurometrix

When is Neurometrix's next earnings date?

Neurometrix is scheduled to release its next quarterly earnings announcement on Thursday, October 15th 2020.
View our earnings forecast for Neurometrix

How were Neurometrix's earnings last quarter?

Neurometrix Inc (NASDAQ:NURO) announced its quarterly earnings results on Thursday, October, 17th. The medical device company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The medical device company had revenue of $2.09 million for the quarter, compared to analysts' expectations of $3.94 million. Neurometrix had a negative net margin of 54.20% and a negative return on equity of 112.60%.
View Neurometrix's earnings history

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Neurometrix's stock reverse split on the morning of Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

What price target have analysts set for NURO?

1 brokers have issued 1-year price targets for Neurometrix's stock. Their forecasts range from $5.00 to $5.00. On average, they expect Neurometrix's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 122.2% from the stock's current price.
View analysts' price targets for Neurometrix

Has Neurometrix been receiving favorable news coverage?

News stories about NURO stock have been trending extremely negative on Sunday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurometrix earned a media sentiment score of -4.8 on InfoTrie's scale. They also gave news stories about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.
View the latest news about Neurometrix

Are investors shorting Neurometrix?

Neurometrix saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 371,000 shares, an increase of 97.1% from the June 30th total of 188,200 shares. Based on an average daily trading volume, of 730,800 shares, the short-interest ratio is currently 0.5 days. Approximately 10.0% of the shares of the stock are sold short.
View Neurometrix's Short Interest

Who are some of Neurometrix's key competitors?

What other stocks do shareholders of Neurometrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurometrix investors own include Merit Medical Systems (MMSI), salesforce.com (CRM), NovaBay Pharmaceuticals (NBY), Citigroup (C), Nokia Oyj (NOK), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN), Rewalk Robotics (RWLK) and SMTC (SMTX).

Who are Neurometrix's key executives?

Neurometrix's management team includes the following people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
  • Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
  • Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
  • Dr. Xuan Kong Ph.D., Chief Data Scientist

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

Who are Neurometrix's major shareholders?

Neurometrix's stock is owned by a number of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.99%).
View institutional ownership trends for Neurometrix

Which major investors are buying Neurometrix stock?

NURO stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
View insider buying and selling activity for Neurometrix

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $2.25.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $8.51 million and generates $9.27 million in revenue each year. The medical device company earns $-3,770,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Neurometrix employs 42 workers across the globe.

What is Neurometrix's official website?

The official website for Neurometrix is www.neurometrix.com.

How can I contact Neurometrix?

Neurometrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.